1. Home
  2. SKYE vs VRA Comparison

SKYE vs VRA Comparison

Compare SKYE & VRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • VRA
  • Stock Information
  • Founded
  • SKYE 2012
  • VRA 1982
  • Country
  • SKYE United States
  • VRA United States
  • Employees
  • SKYE N/A
  • VRA N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • VRA Apparel
  • Sector
  • SKYE Health Care
  • VRA Consumer Discretionary
  • Exchange
  • SKYE Nasdaq
  • VRA Nasdaq
  • Market Cap
  • SKYE 73.4M
  • VRA 69.2M
  • IPO Year
  • SKYE N/A
  • VRA 2010
  • Fundamental
  • Price
  • SKYE $2.16
  • VRA $2.20
  • Analyst Decision
  • SKYE Buy
  • VRA Strong Buy
  • Analyst Count
  • SKYE 6
  • VRA 2
  • Target Price
  • SKYE $16.60
  • VRA $4.00
  • AVG Volume (30 Days)
  • SKYE 229.4K
  • VRA 480.0K
  • Earning Date
  • SKYE 08-08-2025
  • VRA 06-11-2025
  • Dividend Yield
  • SKYE N/A
  • VRA N/A
  • EPS Growth
  • SKYE N/A
  • VRA N/A
  • EPS
  • SKYE N/A
  • VRA N/A
  • Revenue
  • SKYE N/A
  • VRA $355,671,000.00
  • Revenue This Year
  • SKYE N/A
  • VRA N/A
  • Revenue Next Year
  • SKYE N/A
  • VRA $3.80
  • P/E Ratio
  • SKYE N/A
  • VRA N/A
  • Revenue Growth
  • SKYE N/A
  • VRA N/A
  • 52 Week Low
  • SKYE $1.14
  • VRA $1.71
  • 52 Week High
  • SKYE $9.73
  • VRA $6.99
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 51.61
  • VRA 50.69
  • Support Level
  • SKYE $2.12
  • VRA $2.11
  • Resistance Level
  • SKYE $2.22
  • VRA $2.51
  • Average True Range (ATR)
  • SKYE 0.19
  • VRA 0.24
  • MACD
  • SKYE -0.02
  • VRA 0.00
  • Stochastic Oscillator
  • SKYE 34.69
  • VRA 39.29

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About VRA Vera Bradley Inc.

Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the most. most of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.

Share on Social Networks: